Frank G Haluska Selected Research

ridaforolimus

12/2016	A phase 1 study of oral ridaforolimus in pediatric patients with advanced solid tumors.
11/2015	Randomized Phase II Trial of Ridaforolimus in Advanced Endometrial Carcinoma.
7/2013	A multicenter, first-in-pediatrics, phase 1, pharmacokinetic and pharmacodynamic study of ridaforolimus in patients with refractory solid tumors.
7/2013	Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients after benefit from prior chemotherapy.
1/2012	Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Frank G Haluska Research Topics

Disease

23	Melanoma (Melanoma, Malignant) 11/2014 - 03/2002
16	Neoplasms (Cancer) 12/2016 - 06/2002
6	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 01/2018 - 11/2012
5	Thrombocytopenia (Thrombopenia) 12/2016 - 10/2006
4	Leukemia 01/2018 - 01/2006
4	Philadelphia Chromosome 01/2018 - 11/2012
3	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 01/2018 - 11/2012
3	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 08/2017 - 05/2004
3	Pancreatitis 01/2016 - 11/2012
3	Neutropenia 01/2016 - 10/2006
3	Exanthema (Rash) 01/2016 - 07/2013
2	Pneumonia (Pneumonitis) 01/2022 - 07/2013
2	Disease Progression 08/2017 - 11/2015
2	Anemia 12/2016 - 11/2015
2	Hypertriglyceridemia 12/2016 - 01/2016
2	Stomatitis 12/2016 - 07/2013
2	Fatigue 12/2016 - 07/2013
2	Hypertension (High Blood Pressure) 12/2016 - 01/2016
2	Neoplasm Metastasis (Metastasis) 12/2016 - 10/2006
2	Hyperglycemia 11/2015 - 07/2013
2	Sarcoma (Soft Tissue Sarcoma) 07/2013 - 01/2012
2	Infections 07/2013 - 10/2006
2	Carcinoma (Carcinomatosis) 02/2008 - 04/2003
2	Necrosis 02/2008 - 04/2003
1	Gastrointestinal Stromal Tumors (Gastrointestinal Stromal Tumor) 01/2022
1	Pulmonary Embolism 01/2022
1	Brain Neoplasms (Brain Tumor) 08/2017
1	Hypercholesterolemia 12/2016
1	Arterial Occlusive Diseases (Arterial Occlusive Disease) 01/2016
1	Arthralgia (Joint Pain) 01/2016
1	Atrial Fibrillation 01/2016
1	Heart Failure 01/2016
1	Endometrial Neoplasms (Endometrial Cancer) 11/2015
1	Diarrhea 11/2015
1	Hematologic Neoplasms (Hematological Malignancy) 06/2013
1	Hemorrhage 10/2006
1	Neuroblastoma 01/2006
1	Lung Neoplasms (Lung Cancer) 05/2004

Drug/Important Bio-Agent (IBA)

6	ponatinibIBA 01/2022 - 11/2012
6	Tyrosine Kinase InhibitorsIBA 12/2016 - 05/2004
5	ridaforolimusIBA 12/2016 - 01/2012
5	Phosphotransferases (Kinase)IBA 02/2016 - 09/2006
5	VaccinesIBA 05/2007 - 06/2002
4	Lipase (Acid Lipase)FDA Link 12/2016 - 11/2012
4	Dacarbazine (DIC)FDA LinkGeneric 11/2014 - 06/2002
4	AntigensIBA 11/2005 - 06/2002
3	TOR Serine-Threonine KinasesIBA 11/2015 - 01/2012
3	Proteins (Proteins, Gene)FDA Link 01/2012 - 01/2006
3	Peptides (Polypeptides)IBA 01/2006 - 07/2002
2	brigatinibIBA 08/2017 - 12/2016
2	CrizotinibIBA 08/2017 - 12/2016
2	Anaplastic Lymphoma KinaseIBA 08/2017 - 12/2016
2	Alanine Transaminase (SGPT)IBA 12/2016 - 01/2016
2	Aspartate Aminotransferases (Aspartate Transaminase)IBA 12/2016 - 01/2016
2	InterferonsIBA 11/2014 - 03/2002
2	Interferon alpha-2 (Roferon-A)FDA Link 11/2014 - 05/2007
2	Interleukin-2 (IL2)IBA 11/2014 - 01/2006
2	Antineoplastic Agents (Antineoplastics)IBA 07/2013 - 04/2004
2	AntibodiesIBA 02/2008 - 04/2003
2	CTLA-4 AntigenIBA 02/2008 - 04/2003
2	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 02/2008 - 04/2003
2	Phosphoric Monoester Hydrolases (Phosphatases)IBA 01/2006 - 05/2003
2	TensinsIBA 01/2006 - 05/2003
2	EpitopesIBA 01/2006 - 11/2005
2	PTEN Phosphohydrolase (PTEN Phosphatase)IBA 01/2006 - 05/2003
1	Biomarkers (Surrogate Marker)IBA 01/2022
1	Dasatinib (BMS 354825)FDA Link 01/2018
1	nilotinib FDA Link 01/2018
1	Imatinib Mesylate (Gleevec)FDA Link 01/2016
1	Progestins (Progestagens)IBA 11/2015
1	MTOR InhibitorsIBA 11/2015
1	Cisplatin (Platino)FDA LinkGeneric 11/2014
1	Vinblastine (Vinblastine Sulfate)FDA Link 11/2014
1	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 11/2014
1	Cyclin-Dependent Kinase Inhibitor p16IBA 07/2013
1	Amylases FDA Link 11/2012
1	Monoclonal AntibodiesIBA 02/2008
1	Temozolomide (Temodar)FDA LinkGeneric 10/2006
1	Thalidomide (Thalomid)FDA Link 10/2006
1	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 10/2006
1	Antisense OligonucleotidesIBA 10/2006
1	oblimersen (G3139)IBA 10/2006
1	Mitogen-Activated Protein KinasesIBA 04/2006
1	Proto-Oncogene Proteins c-akt (Protein Kinase B)IBA 04/2006
1	HLA Antigens (Human Leukocyte Antigens)IBA 01/2006
1	DNA (Deoxyribonucleic Acid)IBA 01/2006
1	g209-2M melanoma peptideIBA 01/2006
1	G280-9V peptideIBA 11/2005
1	HLA-A*02:01 antigenIBA 11/2005
1	ErbB Receptors (EGF Receptor)IBA 05/2004
1	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 05/2004
1	Gefitinib (Iressa)FDA Link 05/2004
1	Granzymes (Granzyme)IBA 04/2004
1	PerforinIBA 04/2004

Therapy/Procedure

9	Therapeutics 12/2016 - 01/2006
6	Drug Therapy (Chemotherapy) 08/2017 - 06/2002
3	Immunotherapy 02/2008 - 04/2006
2	Intravenous Infusions 01/2012 - 10/2006
1	Biological Therapy 11/2014
1	Lymph Node Excision (Lymph Node Dissection) 08/2007